Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India
You may also be interested in...
From Allstar to Insuman, Sanofi Expands ‘Make In India’ Plans
The French drug firm Sanofi is bullish on producing some of its products in India. It first acquired Shantha Biotechnics and it manufacturing capabilities in 2009 and later started making its pen devices locally, and is now setting up a large project to make the human insulin product Insuman.
WHO Does What It Warned: Delists Shantha Biotech's Pentavalent Vaccine Shan5; More Pains For Sanofi-Aventis?
MUMBAI - In a move that could in the short term severely impair the reputation of Hyderabad-based vaccines maker Shantha Biotechnics, now part of Sanofi-Aventis, the World Health Organization has delisted its popular pentavalent vaccine Shan5, which is used by scores of nations as part of their national immunization programs for the prevention against deadly diseases like diphtheria, tetanus, hepatitis B and Hib